Treatment of Trigeminal Herpes Zoster

First-Line Treatment Options

The American College of Physicians recommends valacyclovir 1 gram orally three times daily for 7 days as the first-line treatment for trigeminal herpes zoster due to its superior bioavailability and less frequent dosing compared to acyclovir 1
Alternative options include acyclovir 800 mg orally five times daily for 7 days, which is recommended by the American Academy of Neurology 2
Treatment should be continued until all lesions have scabbed, as suggested by the Infectious Diseases Society of America 2

For immunocompromised patients with severe or disseminated trigeminal herpes zoster, the Centers for Disease Control and Prevention recommends intravenous acyclovir 5-10 mg/kg every 8 hours until clinical improvement occurs 1, 2
The CDC also suggests considering temporary reduction in immunosuppressive medication if applicable for immunocompromised patients 2
For patients with suspected acyclovir-resistant herpes zoster, the CDC recommends foscarnet 40 mg/kg IV every 8 hours until clinical resolution 3, 1

The American Academy of Dermatology suggests that topical antiviral therapy is substantially less effective than systemic therapy and is not recommended 2
The Infectious Diseases Society of America recommends monitoring for complete resolution of lesions and extending treatment if healing is incomplete after the initial treatment period 1, 2

The Centers for Disease Control and Prevention recommends the recombinant zoster vaccine (Shingrix) for adults aged 50 years and older regardless of prior episodes of herpes zoster to prevent recurrent episodes 1, 2
The CDC also suggests considering vaccination after recovery to prevent future episodes 2